switching between glp-1 agonists chart PDF] Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance Beyond a singular focus on

Discover what current research and FDA findings reveal about mental health risks with semaglutide, tirzepatide, and other GLP-1 medications for diabetes and weight management.

Background Glucagon-like peptide-1 (GLP-1) induces diuresis and natriuresis

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss

hazard ratio 1.60, 95% CI 1.37 to 1.87) but not after confounding factors were accounted for (0.91, 0.73 to 1.12)

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives